Bausch + Lomb announced Ophthalmology and Therapy has published results from a phase 4 study which assessed early patient-reported outcomes with MIEBO in patients with dry eye disease (DED). MIEBO, indicated for the signs and symptoms of DED, is the first and only prescription treatment to directly target tear evaporation. These results shed light on the benefits of MIEBO after the first use and during the first two weeks of treatment. These data build on results from the GOBI and MOJAVE pivotal studies in which patients experienced significant improvement in the signs and symptoms of DED as early as day 15, with continued improvement through day 57.
“We know that the symptoms of dry eye disease, which include eye dryness, blurred vision, burning, stinging and eye pain, can have a significant impact on daily activities such as reading, driving, working on a computer and using devices,” said Andrew Stewart, president, Global Pharmaceuticals and International Consumer, Bausch + Lomb. “These study results build on an impressive data set showing MIEBO as a well-tolerated and effective treatment option for dry eye disease that also can deliver much-needed, fast-acting symptom relief. In particular, the study answers the question of how quickly patients can experience relief prior to day 15, which was the first evaluation point in the phase 3 studies.”
The prospective, multicenter, open-label phase 4 study evaluated the effect of MIEBO on symptom severity and frequency early in treatment.* Inclusion criteria aligned with the phase 3 studies where all patients had a history of dry eye disease and evidence of meibomian gland dysfunction. Patients completed early outcome surveys during four clinic visits (day 1 [pretreatment; 5 and 60 minutes post-first administration] and days 3, 7, and 14). Patients rated symptom severity, symptom frequency and treatment satisfaction on a visual analog scale (VAS) from 0 to 100.
“Rapid relief of dry eye symptoms is an important factor for adherence to treatment,” said Shane R. Kannarr, OD, study author and optometrist at Kannarr Eye Care in Kansas. “These patient-reported results show that MIEBO provided relief from dry eye symptoms quickly – in some cases in as little as five minutes after the patient’s first use – and that relief was maintained and improved over the two-week period. The study also demonstrated high patient treatment satisfaction, another important element for patient compliance, and patients described the product as silky, smooth and soothing.”
For more information click here.
